The Alliance is an experienced multi-institutional cancer clinical trials group that has been reorganized in response to the Institute of Medicine (lOM) consensus report and NCI directives for cooperative group reorganization. Alliance provides a comprehensive and highly efficient clinical trials infrastructure, access to experienced collaborators across all disciplines of oncology clinical trials research, and a diverse portfolio f trials for patients with breast, gastrointestinal, genitourinary, respiratory, central nervous systm, hematological malignancies, and selected rare tumors. Particular strengths of the Alliance include the long-standing tradition of collaborative research of the legacy members, including many who have participated in cooperative group research since its inception in 1955. The Mission of the Alliance for Clinical Trials in Oncology is to reduce the impact of cancer by: - Conducting high quality multidisciplinary cancer control, prevention, and treatment trials that engage a comprehensive research network;- Furthering our understanding of the biological basis of the cancer process and its treatment;from discovery, to validation, to clinical practice;- Providing a scientific and operational infrastructure for innovative clinical and translational research in the academic and community settings.

Public Health Relevance

To reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180821-01
Application #
8605633
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-17
Project End
2019-02-28
Budget Start
2014-04-17
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02115
Phipps, Amanda I; Shi, Qian; Zemla, Tyler J et al. (2018) Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev 27:696-703
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncol 4:783-790
Ristau, Benjamin T; Manola, Judi; Haas, Naomi B et al. (2018) Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol 199:53-59
Rosenkranz, Kari M; Ballman, Karla; McCall, Linda et al. (2018) The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Ann Surg Oncol 25:2858-2866
Urbanic, James J; Wang, Xiaofei; Bogart, Jeffrey A et al. (2018) Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys 101:177-185
Rizzotto, Lara; Lai, Tzung-Huei; Bottoni, Arianna et al. (2018) Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. Leuk Lymphoma 59:1461-1465
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Cheng, Ting-Yuan David; Darke, Amy K; Redman, Mary W et al. (2018) Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst 110:734-742
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021

Showing the most recent 10 out of 325 publications